Citadel Advisors
MRTX

Citadel Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Citadel Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,300
Closed -$2.49M – 15834
2023
Q4 		$2.49M Sell
42,300
-12,400
-23% -$697K ﹤0.01% 4987
2023
Q3 		$2.38M Sell
54,700
-2,000
-4% -$71.4K ﹤0.01% 4899
2023
Q2 		$2.05M Sell
56,700
-13,900
-20% -$573K ﹤0.01% 5112
2023
Q1 		$2.62M Sell
70,600
-86,100
-55% -$3.87M ﹤0.01% 4873
2022
Q4 		$7.1M Buy
156,700
+65,800
+72% +$4.26M ﹤0.01% 3305
2022
Q3 		$6.35M Buy
90,900
+24,100
+36% +$1.78M ﹤0.01% 3481
2022
Q2 		$4.48M Buy
66,800
+15,500
+30% +$986K ﹤0.01% 4010
2022
Q1 		$4.22M Sell
51,300
-15,400
-23% -$1.57M ﹤0.01% 4517
2021
Q4 		$9.78M Sell
66,700
-13,400
-17% -$2.08M ﹤0.01% 3114
2021
Q3 		$14.2M Buy
80,100
+25,300
+46% +$4.07M ﹤0.01% 2505
2021
Q2 		$8.85M Buy
54,800
+800
+1% +$128K ﹤0.01% 3284
2021
Q1 		$9.25M Sell
54,000
-22,300
-29% -$4.42M ﹤0.01% 3088
2020
Q4 		$16.8M Sell
76,300
-16,400
-18% -$3.55M ﹤0.01% 1998
2020
Q3 		$15.4M Buy
92,700
+19,800
+27% +$2.71M ﹤0.01% 1812
2020
Q2 		$8.32M Sell
72,900
-19,200
-21% -$1.86M ﹤0.01% 2445
2020
Q1 		$7.08M Sell
92,100
-9,600
-9% -$861K ﹤0.01% 2273
2019
Q4 		$13.1M Sell
101,700
-173,900
-63% -$16.8M 0.01% 1927
2019
Q3 		$21.5M Buy
275,600
+53,300
+24% +$5M 0.01% 1397
2019
Q2 		$22.9M Buy
222,300
+182,900
+464% +$14.2M 0.01% 1300
2019
Q1 		$2.89M Buy
39,400
+16,200
+70% +$1.1M ﹤0.01% 3828
2018
Q4 		$984K Sell
23,200
-44,500
-66% -$1.77M ﹤0.01% 5338
2018
Q3 		$3.19M Buy
67,700
+51,100
+308% +$2.84M ﹤0.01% 3631
2018
Q2 		$818K Buy
+16,600
New +$627K ﹤0.01% 5553

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's MRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 66,611 shares — an estimated $3.91M sold.

Citadel Advisors first reported a position in MRTX in Q3 2015 and held it in 31 quarters. The position peaked at $73.9M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Citadel Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 66,611 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.91M.
  • Citadel Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 31 quarters.
  • Citadel Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $73.9M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.